Clinical Trials
6
4 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
3
50.0%
Completed
2
33.3%
Enrolling By Invitation
1
16.7%
No approval data available
- Catherine L'Estrange, an 11-year-old from London, is the first UK patient and only the second globally to receive MeiraGTx's gene therapy targeting BBS10-associated retinal degeneration. - The hour-long procedure at St Helier Hospital involved injecting healthy copies of the BBS10 gene directly into the retina to stabilize or potentially improve vision. - Bardet-Biedl syndrome affects approximately one in 100,000 UK births, with patients typically progressing to blindness by their late teens or early twenties. - Early feedback from treated patients and families has been promising, though full results will take years to confirm, according to consultant surgeon Neruban Kumaran.
- MeiraGTx has entered into an asset purchase agreement with Johnson & Johnson to reacquire botaretigene sparoparvovec (bota-vec) for treating X-linked retinitis pigmentosa, paying $25 million upfront plus milestone payments and royalties. - The Phase 3 LUMEOS trial demonstrated statistically significant improvements across multiple vision domains, with 45% of treated patients gaining more than 10 letters in low luminance visual acuity and 40% showing improvement in two or more endpoints. - MeiraGTx plans to file for regulatory approval in the U.S., EU, and Japan immediately, targeting a potential commercial launch in 2027 for a disease affecting over 20,000 patients with no current treatment options. - The company has already completed manufacturing process qualification and holds commercial licenses for its London manufacturing facility, positioning it to supply patients immediately upon regulatory approval.
- The FDA granted Breakthrough Therapy Designation to MeiraGTx's AAV2-hAQP1 gene therapy for treating Grade 2 and Grade 3 radiation-induced xerostomia in cancer patients. - The designation was supported by 3-year data from a Phase 1 dose escalation study, with the Phase 2 AQUAx2 trial currently enrolling final patients. - MeiraGTx anticipates potential BLA filing in the first half of 2027 and US market launch targeted for early 2028. - The company secured significant strategic partnerships with Eli Lilly ($75 million upfront) and Hologen AI ($200 million upfront) to advance its gene therapy pipeline.
- ZipBio and MeiraGTx announced an exclusive licensing agreement for first-in-class AAV gene therapies targeting geographic atrophy through the complement pathway. - The partnership combines MeiraGTx's expertise in genetic medicines and manufacturing with ZipBio's COMPACT™ AI platform for designing novel protein therapeutics. - The agreement includes upfront payments plus milestone and royalty payments, though specific financial terms were not disclosed. - ZipBio's COMPACT™ platform enables creation of compact, multifunctional, and logic-gated proteins that target previously undruggable disease pathways.
- Cell and gene therapy venture capital deals dropped by 66% from 2021 to 2025, with average deal values falling to just $60 million according to GlobalData analysis. - Major pharmaceutical companies including Galapagos and Takeda have abandoned their cell therapy divisions, pivoting toward less risky modalities like antibody-drug conjugates. - Despite funding challenges, Eli Lilly invested over $2 billion in CGT acquisitions including MeiraGTx, Adverum Biotechnologies, and Rznomics for specialized therapeutic applications. - The CGT market is projected to grow at 34.2% annually through 2031, though companies face ongoing regulatory complexity and manufacturing scalability challenges.
- MeiraGTx received FDA RMAT designation for AAV-GAD in Parkinson's disease and aligned with the FDA on its Phase 2 AQUAx2 study for radiation-induced xerostomia to support potential BLA filing. - The company demonstrated significant disease-modifying effects in Parkinson's disease through FDG-PET imaging data showing changes in pathological basal ganglia circuitry, including the substantia nigra. - MeiraGTx is preparing to file for regulatory approval of AAV-AIPL1 for LCA4 in Q4 2025, with all 11 treated children showing meaningful responses and those blind at birth now able to see. - The company secured $200 million in funding through its strategic collaboration with Hologen AI to advance AAV-GAD development and other CNS therapies.
- MeiraGTx presented four posters at ASGCT 2025, showcasing advancements in gene therapies for severe pediatric obesity, ALS, and frontotemporal dementia, highlighting their innovative approach to addressing significant unmet medical needs. - The company's optimized AAV-BDNF vector for obesity demonstrated remarkable efficacy in preclinical models, achieving up to 40% weight loss compared to just 12% with semaglutide, while maintaining normal behavioral patterns in treated animals. - MeiraGTx has developed novel CAG promoter variants that are both shorter and up to 15-fold more potent than traditional promoters, potentially enabling lower therapeutic doses and improved safety profiles for future gene therapy applications.
• MeiraGTx has secured a strategic collaboration with Hologen AI that includes a $200 million upfront payment and the formation of a joint venture with an additional $230 million in committed capital to advance AAV-GAD gene therapy for Parkinson's disease. • The partnership creates the first neuro-AI clinical drug development company, combining MeiraGTx's gene therapy expertise with Hologen's AI technology to transform CNS drug development for neurodegenerative and neuropsychiatric disorders. • Recent clinical data showed AAV-GAD therapy demonstrated significant benefits in Parkinson's disease patients, with meaningful improvements in motor function (UPDRS Part 3) and quality of life measures (PDQ-39).
- Mass General Brigham's corneal stem cell therapy trial demonstrates positive outcomes across all enrolled patients, marking a significant advancement in regenerative eye treatment. - The breakthrough coincides with promising developments in gene-based eye care, including MeiraGTx's gene therapy showing vision improvements in congenitally blind children. - Emmecell's non-surgical cell therapy candidate EO2002 achieves positive topline results in Phase I extension trial for corneal edema treatment.
- A groundbreaking gene therapy developed by Moorfields Eye Hospital and MeiraGTx has successfully restored vision in children born with LCA-AIPL1, a severe inherited eye disorder affecting 2-3 in 10 million newborns. - Clinical trials demonstrated significant vision improvement in all eleven treated children, with some achieving 20/80 vision, enabling them to identify pictures, safely navigate, and engage in visual activities for the first time. - The treatment must be administered before age four due to irreversible retinal degeneration, with regulatory approval expected within 1-2 years following successful safety and efficacy demonstrations.
